Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 437


Immune checkpoint imaging in oncology - a game changer towards personalized immunotherapy?

Lütje S, Feldmann G, Essler M, Brossart P, Bundschuh RA.

J Nucl Med. 2020 Jan 10. pii: jnumed.119.237891. doi: 10.2967/jnumed.119.237891. [Epub ahead of print]


The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy.

Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, Essler M, Holdenrieder S, Ahmadzadehfar H.

Prostate. 2020 Jan;80(1):17-27. doi: 10.1002/pros.23912. Epub 2019 Oct 3.


EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress.

Bisht S, Nolting J, Wenzel J, Brossart P, Feldmann G.

J Oncol. 2019 Mar 4;2019:8701824. doi: 10.1155/2019/8701824. eCollection 2019.


Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.

Yordanova A, Ahrens H, Feldmann G, Brossart P, Gaertner FC, Fottner C, Weber MM, Ahmadzadehfar H, Schreckenberger M, Miederer M, Essler M.

Clin Nucl Med. 2019 May;44(5):e329-e335. doi: 10.1097/RLU.0000000000002532.


[Leukemia caused by collision with a wild pig?]

Zimmermann M, Bendas G, Feldmann G.

Dtsch Med Wochenschr. 2019 Mar;144(5):335-339. doi: 10.1055/a-0826-2446. Epub 2019 Mar 5. German.


Animal models for modeling pancreatic cancer and novel drug discovery.

Bisht S, Feldmann G.

Expert Opin Drug Discov. 2019 Feb;14(2):127-142. doi: 10.1080/17460441.2019.1566319. Epub 2019 Jan 18.


Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, Gaertner FC, Essler M, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1073-1080. doi: 10.1007/s00259-018-4222-x. Epub 2018 Nov 24.


Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.

Schmitt A, Feldmann G, Zander T, Reinhardt HC.

Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28. Review.


Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma.

Bisht S, Brossart P, Feldmann G.

Oncol Res Treat. 2018;41(10):590-594. doi: 10.1159/000493868. Epub 2018 Sep 28. Review.


'Diseases Desperate Grown by Desperate Appliance Are Relieved, or Not at all' - Towards Finding a Cure for Pancreatic Cancer, Where Do We Stand Today?

Feldmann G, Brossart P, Maitra A.

Oncol Res Treat. 2018;41(10):588-589. doi: 10.1159/000493023. Epub 2018 Sep 28. No abstract available.


Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts.

Bisht S, Feldmann G.

Oncol Res Treat. 2018;41(10):596-602. doi: 10.1159/000493437. Epub 2018 Sep 28. Review.


[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].

Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M.

Urologe A. 2018 Jun;57(6):709-713. doi: 10.1007/s00120-018-0642-2. German.


Theranostics in nuclear medicine practice.

Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, Feldmann G, Ahmadzadehfar H, Essler M.

Onco Targets Ther. 2017 Oct 3;10:4821-4828. doi: 10.2147/OTT.S140671. eCollection 2017. Review.


Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role.

Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G.

J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.


Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer.

Lerbs T, Bisht S, Schölch S, Pecqueux M, Kristiansen G, Schneider M, Hofmann BT, Welsch T, Reissfelder C, Rahbari NN, Fritzmann J, Brossart P, Weitz J, Feldmann G, Kahlert C.

BMC Cancer. 2017 Apr 7;17(1):249. doi: 10.1186/s12885-017-3225-5.


The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer.

Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, Essler M, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1473-1479. doi: 10.1007/s00259-017-3681-9. Epub 2017 Mar 23.


A Step-by-Step Clinical Approach for the Management of Neuroendocrine Tumours.

Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, Schmidt-Wolf I, Lingohr P, Fischer S, Kristiansen G, Essler M.

Horm Metab Res. 2017 Feb;49(2):77-85. doi: 10.1055/s-0042-121894. Epub 2017 Jan 18. Review.


Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.

Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, Hauser S, Feldmann G, Essler M, Ahmadzadehfar H.

J Nucl Med. 2017 Feb;58(2):312-319. doi: 10.2967/jnumed.116.178228. Epub 2016 Sep 1.


A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.

Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, Feldmann G.

J Nanobiotechnology. 2016 Jul 11;14(1):57. doi: 10.1186/s12951-016-0209-6.


The GSK3β inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level.

Thongon N, Castiglioni I, Zucal C, Latorre E, D'Agostino V, Bauer I, Pancher M, Ballestrero A, Feldmann G, Nencioni A, Provenzani A.

Oncotarget. 2016 May 3;7(18):26551-66. doi: 10.18632/oncotarget.8437.


Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.

Bisht S, Nolting J, Schütte U, Haarmann J, Jain P, Shah D, Brossart P, Flaherty P, Feldmann G.

Transl Oncol. 2015 Aug;8(4):295-307. doi: 10.1016/j.tranon.2015.06.002.


The Yes-associated protein controls the cell density regulation of Hedgehog signaling.

Tariki M, Dhanyamraju PK, Fendrich V, Borggrefe T, Feldmann G, Lauth M.

Oncogenesis. 2014 Aug 11;3:e112. doi: 10.1038/oncsis.2014.27.


Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles.

Lemoinne S, Cadoret A, Rautou PE, El Mourabit H, Ratziu V, Corpechot C, Rey C, Bosselut N, Barbu V, Wendum D, Feldmann G, Boulanger C, Henegar C, Housset C, Thabut D.

Hepatology. 2015 Mar;61(3):1041-55. doi: 10.1002/hep.27318. Epub 2015 Jan 22.


Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.

Schütte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart P, Feldmann G.

Transl Oncol. 2014 Apr;7(2):309-21. doi: 10.1016/j.tranon.2014.02.005. Epub 2014 Mar 4.


MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease.

Girard M, Lacaille F, Verkarre V, Mategot R, Feldmann G, Grodet A, Sauvat F, Irtan S, Davit-Spraul A, Jacquemin E, Ruemmele F, Rainteau D, Goulet O, Colomb V, Chardot C, Henrion-Caude A, Debray D.

Hepatology. 2014 Jul;60(1):301-10. doi: 10.1002/hep.26974. Epub 2014 May 27.


Molecular diagnostics of pancreatic cysts.

Matthaei H, Feldmann G, Lingohr P, Kalff JC.

Langenbecks Arch Surg. 2013 Dec;398(8):1021-7. doi: 10.1007/s00423-013-1116-z. Epub 2013 Sep 26. Review.


Targeting cancer with a bi-functional peptide: in vitro and in vivo results.

Meschenmoser K, Kim Y, Franken S, Nowak M, Feldmann G, Bendas G, Wolfgarten M, Messmer D, Schmidt-Wolf IG.

In Vivo. 2013 Jul-Aug;27(4):431-42.


Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature.

Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M.

Case Rep Oncol. 2013 Apr 20;6(1):229-35. doi: 10.1159/000351125. Print 2013 Jan.


Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.

Bisht S, Feldmann G, Brossart P.

Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):777-88. doi: 10.1517/17425255.2013.791281. Epub 2013 Apr 16. Review.


Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment.

Feldmann G, Brossart P, von Lilienfeld-Toal M.

Ann Hematol. 2013 Nov;92(11):1577-9. doi: 10.1007/s00277-013-1748-7. Epub 2013 Apr 13. No abstract available.


Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR.

Clin Cancer Res. 2013 Mar 1;19(5):1139-46. doi: 10.1158/1078-0432.CCR-12-2127. Epub 2013 Jan 22.


The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.

Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.


Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.

Nischalke HD, Schmitz V, Luda C, Aldenhoff K, Berger C, Feldmann G, Sauerbruch T, Spengler U, Nattermann J.

PLoS One. 2012;7(8):e42141. doi: 10.1371/journal.pone.0042141. Epub 2012 Aug 7.


Everolimus for the treatment of pancreatic neuroendocrine tumors.

Feldmann G, Bisht S, Schütte U, Haarmann J, Brossart P.

Expert Opin Pharmacother. 2012 Oct;13(14):2073-84. doi: 10.1517/14656566.2012.713348. Epub 2012 Aug 8. Review.


Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas.

Fendrich V, Oh E, Bang S, Karikari C, Ottenhof N, Bisht S, Lauth M, Brossart P, Katsanis N, Maitra A, Feldmann G.

Neoplasia. 2011 Oct;13(10):923-30.


Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD.

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.


Changes in autophagic response in patients with chronic hepatitis C virus infection.

Rautou PE, Cazals-Hatem D, Feldmann G, Mansouri A, Grodet A, Barge S, Martinot-Peignoux M, Duces A, Bièche I, Lebrec D, Bedossa P, Paradis V, Marcellin P, Valla D, Asselah T, Moreau R.

Am J Pathol. 2011 Jun;178(6):2708-15. doi: 10.1016/j.ajpath.2011.02.021.


Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.

Cancer Biol Ther. 2011 Jun 1;11(11):959-68. Epub 2011 Jun 1.


Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research.

Schütte U, Bisht S, Brossart P, Feldmann G.

Expert Opin Drug Discov. 2011 Jan;6(1):33-48. doi: 10.1517/17460441.2011.534453. Epub 2010 Nov 19.


Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway.

Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, Liu S, Leach SD, Maitra A, Mendell JT.

Genes Dev. 2010 Dec 15;24(24):2754-9. doi: 10.1101/gad.1950610.


Agents targeting the Hedgehog pathway for pancreatic cancer treatment.

Bisht S, Brossart P, Maitra A, Feldmann G.

Curr Opin Investig Drugs. 2010 Dec;11(12):1387-98. Review.


The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.

Cancer Biol Ther. 2010 Nov 15;10(10):1009-18. doi: 10.4161/cbt.10.10.13248. Epub 2010 Nov 15.


Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.

Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A, Maitra A.

Mol Cancer Ther. 2010 Aug;9(8):2255-64. doi: 10.1158/1535-7163.MCT-10-0172. Epub 2010 Jul 20.


In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C.

Asselah T, Bièche I, Mansouri A, Laurendeau I, Cazals-Hatem D, Feldmann G, Bedossa P, Paradis V, Martinot-Peignoux M, Lebrec D, Guichard C, Ogier-Denis E, Vidaud M, Tellier Z, Soumelis V, Marcellin P, Moreau R.

J Pathol. 2010 Jul;221(3):264-74. doi: 10.1002/path.2703.


Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.

Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A, Nelkin BD.

Cancer Res. 2010 Jun 1;70(11):4460-9. doi: 10.1158/0008-5472.CAN-09-1107. Epub 2010 May 18.


In vivo and in vitro propagation of intraductal papillary mucinous neoplasms.

Kamiyama H, Kamiyama M, Hong SM, Karikari CA, Lin MT, Borges MW, Griffith M, Young A, Norris-Kirby A, Lubek C, Mizuma M, Feldmann G, Shi C, Liang H, Goggins MG, Maitra A, Hruban RH, Eshleman JR.

Lab Invest. 2010 May;90(5):665-73. doi: 10.1038/labinvest.2010.51. Epub 2010 Mar 15.


In vitro models of pancreatic cancer for translational oncology research.

Feldmann G, Rauenzahn S, Maitra A.

Expert Opin Drug Discov. 2009 Apr 1;4(4):429-443.


The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.

Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK.

Gut. 2010 May;59(5):630-7. doi: 10.1136/gut.2009.188961. Epub 2009 Nov 1.


Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.

Ahlenstiel G, Woitas RP, Iwan A, Nattermann J, Feldmann G, Rockstroh JK, Oldenburg J, Kupfer B, Sauerbruch T, Spengler U.

Immunol Invest. 2009;38(3-4):284-96.


Expression of the transcription factor snail and its target gene twist are associated with malignancy in pheochromocytomas.

Waldmann J, Slater EP, Langer P, Buchholz M, Ramaswamy A, Walz MK, Schmid KW, Feldmann G, Bartsch DK, Fendrich V.

Ann Surg Oncol. 2009 Jul;16(7):1997-2005. doi: 10.1245/s10434-009-0480-y. Epub 2009 May 2.


Supplemental Content

Loading ...
Support Center